Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics: Reiteration of My Long Standing Buy Recommendation Based on an Extraordinary Pipeline (CYTK, $12.90, Buy)

Investment Overview and Thesis

Investment Overview

Cytokinetics reported 2Q, 2017 sales and earnings results on Wednesday, August 2 but this was relatively…
Read more…

Cytokinetics: Phase 3 Trial for Tirasemtiv About to Begin with Topline Results Possible in 2H, 2016; Successful Outcome Could Make the Stock a Homerun (CYTK, $6.35, Buy, For Paid Subscribers)

Introduction

Management has recently provided details of the upcoming phase 3 trial of tirasemtiv in the treatment of ALS; this trial…
Read more…